We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+8.56%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$14.8B
AUM Growth
+$1.79B
(+14%)
Cap. Flow
+$849M
Cap. Flow
% of AUM
5.76%
Top 10 Holdings %
Top 10 Hldgs %
16.89%
Holding
1,178
New
178
Increased
473
Reduced
324
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$128M |
| 2 |
Intel
INTC
|
+$88.4M |
| 3 |
Prudential Financial
PRU
|
+$72.7M |
| 4 |
Lam Research
LRCX
|
+$62.6M |
| 5 |
SBA Communications
SBAC
|
+$58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$98.3M |
| 2 |
Target
TGT
|
+$86.8M |
| 3 |
Occidental Petroleum
OXY
|
+$74.7M |
| 4 |
Synchrony
SYF
|
+$61.6M |
| 5 |
Intercontinental Exchange
ICE
|
+$57.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.69% |
| 2 | Healthcare | 13.54% |
| 3 | Financials | 13.08% |
| 4 | Consumer Discretionary | 12.97% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRC
326
DELISTED
MRC Global
MRC
| $8.77M | 0.06% |
932,422
-191,800
| -17% | -$1.95M |
|
327
Bentley Systems
BSY
$9.54B
| $8.67M | 0.06% |
+133,850
| New | +$7.36M |
|
|
MDP
328
DELISTED
Meredith Corporation
MDP
| $8.61M | 0.06% |
198,307
+31,537
| +19% | +$1.12M |
|
|
RRD
329
DELISTED
RR Donnelley & Sons Co.
RRD
| $8.61M | 0.06% |
1,370,375
+472,241
| +53% | +$2.57M |
|
330
Theravance Biopharma
TBPH
$874M
| $8.59M | 0.06% |
591,524
+31,610
| +6% | +$594K |
|
331
Citi Trends
CTRN
$524M
| $8.56M | 0.06% |
98,370
+59,396
| +152% | +$5.47M |
|
332
Merit Medical Systems
MMSI
$4.43B
| $8.5M | 0.06% |
131,438
-19,793
| -13% | -$1.22M |
|
333
Jacobs Solutions
J
$15.9B
| $8.46M | 0.06% |
76,625
+73,536
| +2,381% | +$8.31M |
|
334
Dominion Energy
D
$62.5B
| $8.44M | 0.06% |
114,687
+98,804
| +622% | +$7.63M |
|
335
Kelly Services Class A
KELYA
$526M
| $8.42M | 0.06% |
351,411
+50,016
| +17% | +$1.23M |
|
336
EOG Resources
EOG
$78B
| $8.33M | 0.06% |
99,793
+93,153
| +1,403% | +$7.37M |
|
337
Gossamer Bio
GOSS
$66.5M
| $8.17M | 0.06% |
1,006,479
-54,075
| -5% | -$469K |
|
338
Schneider National
SNDR
$6.59B
| $8.12M | 0.06% |
372,846
+228,480
| +158% | +$5.53M |
|
339
Plains GP Holdings
PAGP
$5.23B
| $8.09M | 0.05% |
677,108
+268,727
| +66% | +$2.86M |
|
340
Astronics
ATRO
$3.45B
| $8.02M | 0.05% |
549,361
-1,865
| -0.3% | -$27K |
|
|
AD
341
Array Digital Infrastructure
AD
$3.02B
| $7.89M | 0.05% |
217,342
+4,397
| +2% | +$163K |
|
342
National Bank Holdings
NBHC
$1.93B
| $7.88M | 0.05% |
208,851
+19,309
| +10% | +$765K |
|
343
PennyMac Financial
PFSI
$4.38B
| $7.84M | 0.05% |
127,034
-131,882
| -51% | -$8.01M |
|
344
Westlake Corp
WLK
$9.46B
| $7.84M | 0.05% |
+87,038
| New | +$8.45M |
|
345
FMC
FMC
$1.42B
| $7.78M | 0.05% |
71,924
-324,653
| -82% | -$37.6M |
|
|
APLS
346
DELISTED
Apellis Pharmaceuticals
APLS
| $7.78M | 0.05% |
123,025
-138,243
| -53% | -$7.13M |
|
|
TGH
347
DELISTED
Textainer Group Holdings limited
TGH
| $7.75M | 0.05% |
229,416
-50,085
| -18% | -$1.48M |
|
348
Cooper-Standard Automotive
CPS
$504M
| $7.73M | 0.05% |
266,605
-29,842
| -10% | -$923K |
|
|
CIVI
349
DELISTED
Civitas Resources
CIVI
| $7.68M | 0.05% |
163,222
-43,446
| -21% | -$1.76M |
|
350
Associated Banc-Corp
ASB
$5.81B
| $7.61M | 0.05% |
+371,347
| New | +$8.2M |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2021 Portfolio in Review
As of Q2 2021, Jacobs Levy Equity Management held 1,178 positions worth $14.8B, up 14% from $13B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Jacobs Levy Equity Management deployed $849M of net new capital in Q2 2021, opening 178 new positions and adding to 473 existing holdings. Its largest new stake was Lam Research: 991,120 shares worth $64.5M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Qualcomm, an estimated $98.3M trimmed.
- Jacobs Levy Equity Management's largest Q2 2021 buy was Lam Research: 991,120 shares worth $64.5M.
- Jacobs Levy Equity Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $128M increase.
- Jacobs Levy Equity Management's biggest Q2 2021 reduction was Qualcomm, cutting an estimated $98.3M.
- Jacobs Levy Equity Management fully exited Occidental Petroleum in Q2 2021, selling an estimated $74.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 17% of its $14.8B portfolio in Q2 2021.
- Jacobs Levy Equity Management opened 178 new positions and closed 161 in Q2 2021.
- Jacobs Levy Equity Management's portfolio value rose 14% quarter-over-quarter to $14.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2021, filed 16 Aug 2021.